Quarterly report pursuant to Section 13 or 15(d)

Warrants (Tables)

v3.19.3
Warrants (Tables)
9 Months Ended
Sep. 30, 2019
Warrants and Rights Note Disclosure [Abstract]  
Summary of Warrant Activity

A summary of warrant activity for the year ended December 31, 2018 and the nine months ended September 30, 2019 is as follows:

 

    Warrants    

Weighted

Average

Price

 
Balance - December 31, 2017     2,177,425     $ 3.10  
Granted     14,700,000       1.00  
Exercised     (9,505,500 )     1.00  
Expired            
Balance - December 31, 2018     7,371,925       1.74  
Granted     19,166,668       0.83  
Exercised            
Expired            
Balance - September 30, 2019     26,538,593     $ 1.08  

Schedule of Warrants Outstanding

The warrants outstanding as of September 30, 2019 are as follows:

 

    Exercise Price     Warrants Outstanding     Expiration Date  
  $ 3.10       48,387       9/19/2022  
    $ 2.00       900,000       4/10/2023  
    $ 3.10       462,106       5/10/2024  
    $ 3.10       602,414       7/25/2024  
    $ 3.10       1,064,518       11/8/2024  
    $ 1.00       4,294,500       7/17/2025  
    $ 0.75       9,583,334       9/25/2020 *
    $ 0.90       9,583,334       3/25/2024  
              26,538,593          

 

* Subject to termination prior to the indicated date following the Company’s release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013 plus twenty-one (21) trading days.